A carregar...
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4519957/ https://ncbi.nlm.nih.gov/pubmed/26204829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms160716414 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|